Patents by Inventor Michael Marks

Michael Marks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
    Publication number: 20110144095
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are as defined herein, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: February 23, 2011
    Publication date: June 16, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMA & CO. KG
    Inventors: Frank HIMMELSBACH, Michael MARK, Matthias ECKHARDT, Elke LANGKOPF, Roland MAIER, Ralf LOTZ
  • PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES
    Publication number: 20110112069
    Abstract: The specification describes the use of selected purine derivatives for the treatment of hyperproliferative diseases.
    Type: Application
    Filed: August 15, 2008
    Publication date: May 12, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Frank Himmelsbach, Michael Mark, Mohammad Tadayyon, Leo Thomas
  • PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR
    Publication number: 20110098240
    Abstract: The invention relates to a pharmaceutical composition according to claim 1 comprising a SGLT2 inhibitor in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: August 15, 2008
    Publication date: April 28, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Klaus Dugi, Michael Mark, Frank Himmelsbach
  • DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD
    Publication number: 20110092510
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing non alcoholic fatty liver diseases (NAFLD).
    Type: Application
    Filed: June 2, 2009
    Publication date: April 21, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thomas Klein, Michael Mark, Heiko Niessen, Leo Thomas
  • USES OF DPP-IV INHIBITORS
    Publication number: 20110065731
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Application
    Filed: November 15, 2010
    Publication date: March 17, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Klaus DUGI, Frank HIMMELSBACH, Michael MARK
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20110046087
    Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: February 11, 2010
    Publication date: February 24, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli BROEDL, Rolf GREMPLER
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20110046076
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: February 11, 2010
    Publication date: February 24, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Broedl, Rolf Grempler
  • NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER
    Publication number: 20100323014
    Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, a poorly aqueous soluble non-ionizable cellulosic polymer, and a poorly aqueous soluble polymeric amphiphilic non-ionizable block copolymer.
    Type: Application
    Filed: May 26, 2008
    Publication date: December 23, 2010
    Inventors: Corey Jay Bloom, Marshall David Crew, Warren Kenyon Miller, Michael Mark Morgen, Daniel Tod Smithey
  • Xanthine derivates, their preparation and their use in pharmaceutical compositions
    Patent number: 7838529
    Abstract: Compounds of formula (I) wherein R1 is a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by R10 and R11 and R2 to R4 and R10 and R1l are defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type II diabetes mellitus and obesity using these compounds.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: November 23, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Michael Mark, Roland Maier, Ralf Lotz
  • NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS
    Publication number: 20100215747
    Abstract: A pharmaceutical composition comprises nanoparticles comprising ionizable, poorly water soluble cellulosic polymers.
    Type: Application
    Filed: June 30, 2008
    Publication date: August 26, 2010
    Inventors: Corey Jay Bloom, Marshall David Crew, Dwayne T. Friesen, Warren Kenyon Miller, Michael Mark Morgen, Daniel Tod Smithey
  • Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
    Publication number: 20100204250
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are as defined herein, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: April 27, 2010
    Publication date: August 12, 2010
    Applicant: Boehringer Ingelheim Pharma & Co. KG
    Inventors: Frank HIMMELSBACH, Michael MARK, Matthias ECKHARDT, Elke LANGKOPF, Roland MAIER, Ralf LOTZ
  • Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
    Publication number: 20100173916
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: March 16, 2010
    Publication date: July 8, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Frank HIMMELSBACH, Michael MARK, Matthias ECKHARDT, Elke LANGKOPF, Roland MAIER, Ralf R.H. LOTZ
  • XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
    Publication number: 20100144703
    Abstract: Disclosed are substituted xanthines of general formula wherein R1 to R4 are defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: February 17, 2010
    Publication date: June 10, 2010
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank HIMMELSBACH, Elke LANGKOPF, Matthias ECKHARDT, Roland MAIER, Michael MARK, Mohammad TADAYYON, Ralf R. H. LOTZ
  • Screen assembly
    Patent number: 7730932
    Abstract: The present invention broadly includes a screen assembly including a U-shaped channel, a plurality of channels, and a plurality of retainer clips. Each channel in the plurality of channels includes respective first and second walls forming an L-shape and a respective third wall hingedly connected to the respective first wall. The respective first, second, and third walls form a U-shape when the respective third wall is in a closed position. The plurality of channels are arranged to receive a screen frame when the respective third wall is in an open position and the plurality of channel elements is arranged to restrain the screen frame when the respective third wall is in the closed position. The plurality of retainer clips is arranged to releasably engage the plurality of channels to maintain the respective third wall in the closed position.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: June 8, 2010
    Inventors: Kenneth W. Bauer, Michael Marks
  • NANOPARTICLES COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND ANON-IONIZABLE POLYMER
    Publication number: 20100129447
    Abstract: A pharmaceutical composition comprises nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a poorly aqueous soluble non-ionizable polymer.
    Type: Application
    Filed: April 23, 2008
    Publication date: May 27, 2010
    Inventors: Corey Jay Bloom, Marshall David Crew, Daniel Tod Smithey, Warren Kenyon Miller, Michael Mark Morgen
  • NANOPARTICLES COMPRISING A DRUG,ETHYCELLULOSE,AND A BILE SALT
    Publication number: 20100119603
    Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, ethylcellulose, and a bile salt.
    Type: Application
    Filed: April 21, 2008
    Publication date: May 13, 2010
    Inventors: warren Kenyon Miller, Michael Mark Morgen, Daniel Tod Smithey
  • NANOPARTICLES COMPRISING NON-CRYSTALLINE DRUG
    Publication number: 20100119612
    Abstract: A pharmaceutical composition comprises nanoparticles comprising a core of non-crystalline drug and surface stabilizers consisting of a phospholipid and a bile salt.
    Type: Application
    Filed: April 7, 2008
    Publication date: May 13, 2010
    Inventors: Dwayne Thomas Friesen, Daniel Tod Smithey, Michael Mark Morgen, Ralph Tadday
  • Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
    Patent number: 7696212
    Abstract: Disclosed are substituted xanthines of general formula wherein R1 to R4 are defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: December 10, 2008
    Date of Patent: April 13, 2010
    Assignee: Boehringer Ingelheim Pharma GmbH and Co. KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Roland Maier, Ralf Lotz, Michael Mark, Mohammad Tadayyon
  • PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES COMPRISING ENTERIC POLYMERS CASEIN
    Publication number: 20100062073
    Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and an enteric polymer, and casein.
    Type: Application
    Filed: November 16, 2007
    Publication date: March 11, 2010
    Inventors: Ronald Arthur Beyerinck, Corey Jay Bloom, Marshall David Crew, Dwayne Thomas Friesen, Michael Mark Morgen, Daniel Tod Smithey
  • SYSTEM AND METHOD FOR AUTOMATIC CONFIGURATION OF PORTAL COMPOSITE APPLICATIONS
    Publication number: 20090300341
    Abstract: The present invention is directed to the automatic configuration of portal composite applications.
    Type: Application
    Filed: May 29, 2008
    Publication date: December 3, 2009
    Inventors: Dieter Buehler, Walter Haenel, Izidor Jager, Michael Marks